Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion.
about
Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusionAnti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusionEvaluation of ultrasound-assisted thrombolysis using custom liposomes in a model of retinal vein occlusion.Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalitiesTreatment of branch retinal vein occlusion induced macular edema with bevacizumab.Intravitreous bevacizumab in the treatment of macular edema from branch retinal vein occlusion and hemisphere retinal vein occlusion (an AOS thesis)Visual acuity and foveal thickness after vitrectomy for macular edema associated with branch retinal vein occlusion: a case series.Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels.Batch-related sterile endophthalmitis following intravitreal injection of bevacizumab.Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results.Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis.Recurrence of macular edema associated with branch retinal vein occlusion after intravitreal bevacizumab.Intravitreal bevacizumab treatment for macular edema due to branch retinal vein occlusion in a clinical setting.Direct photocoagulation to leakage points to treat chronic macular edema associated with branch retinal vein occlusion: a pilot studyPredictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusionVisual prognosis and vitreous molecules after vitrectomy for macular edema with branch retinal vein occlusion.Indications for intravitreal bevacizumab in ibadan, sub-saharan Africa.Branch retinal vein occlusion: treatment modalities: an update of the literature.Comparison between Intravitreal Triamcinolone with Grid Laser Photocoagulation versus Bevacizumab with Grid Laser Photocoagulation Combinations for Branch Retinal Vein Occlusion.Intravitreal pegaptanib for refractory macular edema secondary to retinal vein occlusion.Comparative study of combined bevacizumab/targeted photocoagulation vs bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions.Importance of Lid Hygiene Before Ocular Surgery: Qualitative and Quantitative Analysis of Eyelid and Conjunctiva Microbiota.One-year outcome of bevacizumab therapy for chronic macular edema in central and branch retinal vein occlusions in real-world clinical practice in the UK.Analysis of Potential Ischemic Effect of Intravitreal Bevacizumab on Unaffected Retina in Treatment-Naïve Macular Edema Due to Branch Retinal Vein Occlusion: A Prospective, Interventional Case-SeriesFive-year outcomes of pars plana vitrectomy for macular edema associated with branch retinal vein occlusionTherapeutic potential of intravitreal pharmacotherapy in retinal vein occlusionEffects of Vitrectomy on Recurrent Macular Edema due to Branch Retinal Vein Occlusion after Intravitreal Injection of Bevacizumab.Early vitreous hemorrhage after vitrectomy with preoperative intravitreal bevacizumab for proliferative diabetic retinopathy.Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management.Comparison between intravitreal bevacizumab and triamcinolone for macular edema secondary to branch retinal vein occlusionBevacizumab (avastin) in ocular processes other than choroidal neovascularization.Intravitreal bevacizumab: an analysis of the evidence.Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization.Management of retinal vein occlusion--consensus document.Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.Anti-vascular endothelial growth factor treatment for retinal vein occlusions.Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion.Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cellsA 6-month, subject-masked, randomized controlled study to assess efficacy of dexamethasone as an adjunct to bevacizumab compared with bevacizumab alone in the treatment of patients with macular edema due to central or branch retinal vein occlusion.Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results.
P2860
Q24201821-865E7E4E-54A1-42AA-A759-75A13B61A312Q24234750-4041F349-3EFD-4606-99DF-B5CC6AE4C2DCQ30455839-F12E57C8-0885-436E-B1B1-67558B77BC9DQ33320830-6EF3C907-C520-4589-8559-180E4A9E7E20Q33372580-CC6EE4F8-9F33-4C2A-A918-B145022DD815Q33416826-34FA1B55-4F26-43C7-A2B2-28F20D5AAD82Q33568145-B0BB3FD2-6997-4706-BFFF-7468731B6EE3Q33584304-66855A9E-91A4-482A-9517-130830184480Q33780704-36DF173F-A5ED-4933-AC6C-A149904C4412Q33959122-B239C0EF-DE6C-4AF1-90FE-984F5D4A3D47Q33995887-F7679D73-C0C7-473A-AEE4-4DC86E077DE3Q34106112-4CF66C7E-1D91-45A9-9366-2FA87C42F717Q34293412-F0B3A432-026E-4FF4-9DFE-CCF7EA43CFAEQ34352584-C8458579-DE8D-46B4-AB1E-23AB2DD0B5FCQ34588134-1CCDE023-88ED-4503-BDB1-B0747ECC64BDQ34616286-5B7C4F99-1B8B-4FB1-8B01-F79BCCCE7E18Q34648669-958CE0E9-2B04-4CBC-BA4C-CD2AA561E500Q35028773-9986313C-D920-4D00-A25E-FFC785E031AAQ35098562-823EEAA4-BEA5-42AF-939B-4A15147DEAFAQ35122731-45F701F4-9635-4A9B-BC99-985FCCB917D7Q35635355-2B4F59A1-B5FA-4B65-B4AB-126DB9EF9438Q35866525-58F095BE-1E4E-4B2A-BBAB-6E6FD5F1E183Q36111710-6AF2912F-C3FA-46FA-BEB8-12601082082CQ36130147-561C8A35-7CB9-4A70-B1EF-72CA58B7F578Q36296091-A66E080A-57B7-4EBD-999B-9125A98483F6Q36490483-45E27725-7DAE-4850-B572-AB1832D84EABQ36663998-BC264030-071C-45B4-8AF7-DFA08DDBD1D6Q36743033-D50888E3-4E40-4F73-80AB-2D5BEA50B63CQ37361517-0616CB08-E01E-40EC-AAAC-D53C43741E79Q37463972-E6E740CF-C470-4C92-B9D2-366805430D7EQ37468754-A06391BE-B6AB-4271-B7DF-93799B0D81A5Q37577410-EB2B8D41-53DB-462E-A4B2-C98ED4562A75Q37627442-0EB91D5F-5B78-4624-949B-9442DAF95D10Q37876127-8C1B4B9A-8AA8-4C49-A2A5-982D85130327Q37910660-5BD8CD35-8CD4-49FB-A000-664D3ACF4B2DQ38003864-46EF78BB-2358-4159-9327-D4B078364A34Q38414123-5E470FEA-1ECB-4CEE-8025-74CB5800243BQ40018607-37E60343-845E-4198-A5FD-3CB7512802F0Q40523257-5A886652-5D06-4A20-AC36-0B787996AC5BQ41774096-0598FCF8-E03E-4A0A-871D-1205F28A003D
P2860
Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Intravitreal bevacizumab (Avas ...... branch retinal vein occlusion.
@en
type
label
Intravitreal bevacizumab (Avas ...... branch retinal vein occlusion.
@en
prefLabel
Intravitreal bevacizumab (Avas ...... branch retinal vein occlusion.
@en
P2093
P1433
P1476
Intravitreal bevacizumab (Avas ...... branch retinal vein occlusion.
@en
P2093
Alessandro A Castellarin
Dante J Pieramici
Ma'an A Nasir
Melvin D Rabena
Robert L Avery
P304
P356
10.1097/IAE.0B013E318030E77E
P577
2007-04-01T00:00:00Z